Compare AU

Compare CURE vs. XALG

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and XALG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

CURE

XALG

Popularity

Low

Low

Pearlers invested

80

1

Median incremental investment

$620.00

$993.50

Median investment frequency

Monthly

Daily

Median total investment

$1,347.53

$1,012.61

Average age group

> 35

< 26


Key Summary

CURE

XALG

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

XALG.AX was created on 2015-12-21 by Alphinity. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform its benchmark after costs and over rolling three-year periods.

Top 3 holdings

Neurocrine Biosciences Inc (2.78 %)

AbbVie Inc (2.58 %)

Alnylam Pharmaceuticals Inc (2.56 %)

Alphinity Global Equity Fund - Active ETF (100 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

0.75 %


Key Summary

CURE

XALG

Issuer

Global X

Alphinity

Tracking index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.45 %

0.75 %

Price

$50.85

$12.34

Size

$34.226 million

N/A

10Y return

N/A

N/A

Annual distribution/ dividend yield (5Y)

4.24 %

1.74 %

Market

ASX

ASX

First listed date

12/11/2018

16/01/2023

Purchase fee

$6.50

$6.50


Community Stats

CURE

XALG

Popularity

Low

Low

Pearlers invested

80

1

Median incremental investment

$620.00

$993.50

Median investment frequency

Monthly

Daily

Median total investment

$1,347.53

$1,012.61

Average age group

> 35

< 26


Pros and Cons

CURE

XALG

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

XALG

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home